How Quickly Does Ebglyss Reduce Itching?
Ebglyss (lebrikizumab-lbkz), an IL-13 inhibitor for moderate-to-severe atopic dermatitis, shows rapid itch relief in clinical trials. Patients reported meaningful reductions in itching as early as week 1, with 40-50% achieving at least a 4-point drop on the Peak Pruritus NRS (a 0-10 itch severity scale) after the first 500 mg dose, followed by 250 mg doses every 2 weeks.[1][2]
Improvement strengthens over time: by week 4, up to 60% hit this threshold, and by week 16, 70-80% of responders saw sustained relief.[1]
What Do Real-World Patients Experience?
In phase 3 trials (ADvocate1, ADvocate2, ADjoin), itch scores dropped by a mean 3.7-4.0 points from baseline by week 16, with some noticing less scratching within days. Patient reports on forums like Drugs.com note relief starting 3-7 days post-injection, though full effects build over 2-4 weeks.[3]
How Does It Compare to Dupixent?
Ebglyss matches Dupixent's speed on itch—both hit significant NRS reductions by week 1-2—but Ebglyss requires only two loading doses (500 mg at weeks 0 and 2), then every 2 weeks or 4 weeks for maintenance, versus Dupixent's weekly initial dosing.[1][4] Head-to-head data is limited.
Factors Affecting Speed of Relief
Response varies by baseline itch severity, prior treatments, and atopic dermatitis extent. Non-responders (about 20-30%) may see minimal change by week 16 and could switch therapies. Weight-based dosing isn't needed, unlike some biologics.[1]
Clinical Trial Timeline for Itch Reduction
| Time Point | % with ≥4-Point Pruritus NRS Improvement |
|------------|------------------------------------------|
| Week 1 | 40-45% [1] |
| Week 2 | 50-55% [1] |
| Week 4 | 55-65% [1] |
| Week 16 | 70-80% [1][2] |
When to Expect Full Results and What If It Doesn't Work?
Peak itch control occurs by weeks 12-16, alongside skin clearance (IGA 0/1 in 40-50%). If no improvement by week 16, guidelines suggest reassessing for IL-13 pathway suitability or trying JAK inhibitors like Cibinqo, which act even faster (days).[5]
[1]: Ebglyss Prescribing Information (FDA)
[2]: NEJM: Lebrikizumab Phase 3 Trials
[3]: Drugs.com Ebglyss Reviews
[4]: Dupixent Prescribing Information
[5]: AAD Atopic Dermatitis Guidelines